Titan Spine, a medical device surface technology company, has signed a distribution agreement with Biomet to bring the Titan Spine Endoskeleton line of interbody fusion devices to practicing spine surgeons in Germany.
Under the agreement, Titan Spine will provide the Endoskeleton line of products to Biomet for distribution in Germany.
The companies will also consider broadening the scope to reach physicians in additional countries within the EU.
The full line of Endoskeleton devices features Titan's proprietary implant surface technology, consisting of a unique combination of roughened topographies at the macro, micro, and cellular levels.
The combination of surface levels is designed to create an optimal host-bone response and actively participate in the fusion process by promoting new bone growth, encouraging natural production of bone morphogenetic proteins (BMPs) and creating the potential for a faster and more robust fusion.
Biomet Global Spine business general manager Jim Cloar noted Biomet is excited about the new partnership with Titan Spine.
"The addition of the Titan interbody fusion technology to Biomet's comprehensive portfolio of spinal solutions will provide surgeons and their patients with a broad offering of innovative treatment options," Cloar added.
Titan Spine vice president of sales, Europe, Marcus Klarl said: "Titan Spine has experienced significant sales growth in the last year in the United States and we are extremely pleased to collaborate with Biomet, a leader in the musculoskeletal and orthopedic spaces, to offer Titan's advanced surface technology to a broader physician base in Europe."
